Breast Arterial Calcification As a Cardiovascular Risk Factor: Time to "Bust" It Out
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M
. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39.
DOI: 10.1016/S0140-6736(18)32590-X.
View
2.
Ledwidge M, Gallagher J, Conlon C, Tallon E, OConnell E, Dawkins I
. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013; 310(1):66-74.
DOI: 10.1001/jama.2013.7588.
View
3.
Margolies L, Yip R, Hwang E, Oudsema R, Subramaniam V, Hecht H
. Breast Arterial Calcification in the Mammogram Report: The Patient Perspective. AJR Am J Roentgenol. 2018; 212(1):209-214.
DOI: 10.2214/AJR.18.20171.
View
4.
Wright A, Carr M, Kontopantelis E, Leelarathna L, Thabit H, Emsley R
. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care. 2022; 45(4):909-918.
DOI: 10.2337/dc21-1113.
View
5.
Koh T, Tan H, Ravi P, Sng J, Yeo T, Tan B
. Association Between Breast Arterial Calcifications and Cardiovascular Disease: A Systematic Review and Meta-analysis. Can J Cardiol. 2023; 39(12):1941-1950.
DOI: 10.1016/j.cjca.2023.07.024.
View